Enzolytics, Inc. (OTCMKTS:ENZC) Sees Large Decline in Short Interest

Enzolytics, Inc. (OTCMKTS:ENZC) was the recipient of a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 1,874 shares, a decrease of 99.5% from the February 12th total of 412,513 shares. Based on an average daily trading volume, of 16,015,665 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily trading volume, of 16,015,665 shares, the days-to-cover ratio is currently 0.0 days.

Enzolytics Stock Performance

Shares of Enzolytics stock traded down $0.00 during trading on Tuesday, hitting $0.00. 13,544,150 shares of the company were exchanged, compared to its average volume of 6,403,851. Enzolytics has a 1-year low of $0.00 and a 1-year high of $0.00.

About Enzolytics

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.